Background: Vitamin D deficiency has been associated with poor prognosis in breast cancer. A new molecular classification of breast cancer is being increasingly used that is based on expression of estrogen receptors, progesterone receptors and Her2/neu amplification and is found to correlate well with prognosis and outcome of disease. The present study was designed to determine serum vitamin D deficiency in these molecular subtypes of breast cancer.
Introduction
In addition to maintaining calcium and phosphate homeostasis, vitamin D has been proposed to have antiproliferative effects on various cancer subtypes. It is believed to retard tumor cell growth and proliferation, promote apoptosis, prevent tumor cell stimulation by growth factors and regulate inflammation, thus affecting tumor microenvironment [1] .Low levels of vitamin D have been shown to be associated with increased mortality and poor prognosis in breast cancer in various studies in different parts of the world. [2, 3, 4] Breast cancer is the most common cancer among Indian urban females. [5] It has classically been classified based on morphologyor histological grade into various types taking into account tumor cell's mitotic index, degree of differentiation and nuclear pleomorphism. [6] However, within morphological and histological subtypes, variation was observed in terms of prognosis and response to therapy. With the advent of microarray based gene expression profiling, various classification systems emerged. Recently, a microarray based molecular classification proposed by Perou and colleagues [7] and validated by others has become the most acceptable classification to determine prognosis. It classifies the breast cancer into luminal A, luminal B, Her2neu enriched and basal type/ triple negative breast cancer (TNBC) based on the tumor cells expression of estrogen receptor(ER), progesterone receptor (PR) or Her2/neu amplification. The status of ER, PR and Her2neu expression is routinely determined by immunohistochemistry and fluorescence in situ hybridization(FISH). [8] Based on a case study in California, that has shown deficient levels of vitamin D in breast cancer patients subtypes according to the above mentioned classification, [9] the present study was planned to determine vitamin D levels in the breast cancer patients as per the molecular classification, to compare the serum vitamin D levels among the various groups of breast cancer patients and also with age matched healthy controls in India. [10]
Materials and Methods
Statistical analysis was performed using SPSS v.16 (SPSS, USA). Non-parametric Mann-Whitney U test was carried out to compare the various groups of breast cancer patients with healthy controls. Unpaired student t-test was performed to match the age of breast cancer patients and healthy controls. Non-parametric kruskal-wallis test followed by Mann-Whitney U test was done to compare these groups with each other. P value <0.05 was considered statistically significant.
Results
The mean age of patients with breast cancer was found to be 55.8 with standard deviation of 10.09. Table 1 shows the sample size, mean, standard deviation and 95% confidence interval of serum vitamin D levels of all the breast cancer patients groups and healthy controls.
The mean serum vitamin D levels in all the groups of breast cancer patients was found to be significantly lower than the healthy controls with p value < 0.05 as shown in 
Discussion
Despite the availability of a large number of studies on the role of vitamin D in breast cancer across the globe, the studies in India are limited. With the advent of new classification based on the receptor status in breast cancer patients, the current study was planned to look for the vitamin D deficiency in various subtypes of breast cancer.
In a country like India where skin pigmentation, milk intolerance along with lifestyle and avoidance of sun exposure already predispose to low vitamin D levels, the deficiency of vitamin D in breast cancer patients can result in poorer prognosis.
With a mean of 17.8 ng/mL of serum vitamin D in the breast cancer patients as compared to the mean of 25.9 ng/ mL in healthy controls, the present study shows agreement with previous studies in Saudi Arabia [11] and in other parts of the world. [2, 3, 4] The present study also shows that levels of vitamin D in triple negative breast cancer with mean of 13.3ng/mL is lowest among all the subtypes. This finding conforms to the earlier studies where vitamin D levels in TNBC have been found to be lowest. [9] Furthermore, there are studies that show that TNBC has the worst prognosis than its other counterparts [12] . Her2neu overexpression is long known to have contribution to aggressive behavior of breast cancer with poor outcomes [13] . Her2neu enriched subtype of breast cancer has been also shown to have unfavourable prognosis as compared to the luminal types. [14] Pertaining to the anti-proliferative and protective effect of vitamin D on cancer cells, its deficiency implies higher proliferation in cancer cells and this could explain lower Annals of Pathology and Laboratory Medicine, Vol. 4, Issue 6, November-December, 2017 levels of vitamin D in the Her2/neu enriched and TNBC subtypes that are more aggressive and are associated with poor outcomes. Contrary to our study, a study by Kim HJ in korea has shown relation of vitamin D deficiency with poor prognosis of luminal types but no relation was shown with her2/neu enriched or TNBC subtype. They have hypothesized it to be due to effect of vitamin D on suppressing estrogen mediated proliferation of breast cancers that are ER positive i.e. luminal type but they have not explained any mechanism for ER negative cancers. [15] However, In a recent study, it was shown that by upregulating the vitamin d receptors in murine model of TNBC, antiproliferative effect is enhanced [16] and thus explaining the effect of vitamin D in TNBC subtype breast cancer. Further studies explaining the exact molecular mechanism underlying such observations needs to be carried out. Moreover, studies with larger sample size involving larger geographical distribution have to be carried out to validate our results.
Studies are also available that show that vitamin D supplementation in breast cancer patients improved their prognosis. [17] One such study showed that intake of high dose weekly vitamin D supplementation can be helpful not only in breast cancer but also in reducing treatment related arthralgias and fractures. [18] In the current study, a lower mean level of vitamin D was observed in both the breast cancer patients as well as healthy controls than the previous studies in western population. The plausible explanation for this could be socio-cultural taboos and vegetarian diet combined with lack of awareness regarding vitamin D supplements in Indian population as explained elsewhere. [10] Their study also showed that mean levels of vitamin D in Punjab, Haryana are around 25.3ng/mL which is close to the mean vitamin D levels in healthy controls (25.95ng/mL) in our study.
The drawback of the current study includes the lower sample size, single geographical area and determination of a single parameter to evaluate prognosis in breast cancer patients. Therefore further studies considering these aspects must be carried out. However, to the best of our knowledge, this is the first study in India, evaluating role of vitamin D deficiency in breast cancer taking into account the molecular subtypes of breast cancer.
To conclude, Vitamin D deficiency is associated more with breast cancer as compared to age matched healthy controls. The Triple negative and her2/neu enriched subtypes that carry poorer prognosis shows higher prevalence and significantly lower mean values of serum vitamin D than the luminal types.
